ESPR

Insider Trades

Name	Value	Action	Price	Current Price
Koenig Sheldon L.Director, Officer: President And CEO $70k25.6k shares SellMar 17, 2026 $2.72 --
Halladay BenjaminChief Financial Officer $17k6.4k shares SellMar 17, 2026 $2.71 --
Looker BenjaminChief Legal Officer $15k5.7k shares SellMar 17, 2026 $2.70 --
Looker BenjaminGeneral Counsel $4.9k1.7k shares SellJan 20, 2026 $2.88 --
Koenig Sheldon L.Director, Officer: President And CEO $177k48.2k shares SellDec 17, 2025 $3.67 --
Halladay BenjaminChief Financial Officer $27k7.3k shares SellDec 17, 2025 $3.67 --

News

businesswire.comEsperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPRbusinesswire.comJun 17

globenewswire.comEsperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026globenewswire.comMay 26

globenewswire.comEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)globenewswire.comMay 14

zacks.comESPR Stock Surges 44% in a Month: Here's What You Need to Knowzacks.comMay 14

globenewswire.comEsperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026globenewswire.comMay 13

Trade ESPR

About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.

CEO: Sheldon L. Koenig
IPO Date: Jun 26, 2013

Market Data

Open: $3.17
High: $3.17
Low: $3.15
Volume: 17M
Avg Volume: 12.3M
52W High: $4.18
52W Low: $0.95

Valuation

Market Cap: $655M
Enterprise Value: $751M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-13M
Revenue: $403M
Net Income: $-23M
Cash: $168M
Debt: $548M

Events

EarningsAug 4

EPS est. -0.02